Otsuka and Lundbeck take schizophrenia to FDA; Takeda's Actos could treat Alzheimer's;

@FierceBiotech: Fresh off Phase III success, Otonomy shoots for an $86M IPO. Story | Follow @FierceBiotech

@JohnCFierce: I'm soon going offline for a week.  will be holding down the fort. Please postpone all big  news until I get back. :) | Follow @JohnCFierce

@DamianFierce: Via @WSJ, $ABBV + $SHPG would leapfrog $LLY. More | Follow @DamianFierce

@EmilyMFierce: Like in Humans, Genes Drive Half of Chimp Intelligence, Study Finds via Article | Follow @EmilyMFierce

> The drug development industry wastes loads of money each year pressing ahead on doomed projects, but how can investigators better determine which programs to kill and which to keep? David Shaywitz addresses the issue in Forbes. Column

> Otsuka and Lundbeck filed an FDA application for brexpiprazole, a treatment for schizophrenia and major depressive disorder. More

> Aerie Pharmaceuticals ($AERI) has kicked off a Phase III trial for Rhopressa, its eye drop designed to relieve in-eye pressure in patients with glaucoma. News

> Takeda's diabetes drug Actos could find a new life as a treatment for Alzheimer's disease, according to a study. Story

Medical Device News

@FierceMedDev: Massachusetts med tech outfit wins $1M from NIH to develop pediatric stent system. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI last week: FDA clears oral sleep apnea device, as search for CPAP alternatives continues. Story | Follow @StacyALawrence

@VarunSaxena2: FDA panel recommends stronger labeling, limiting use of power morcellation--agency may go farther. Article | Follow @VarunSaxena2

@MichaelGFierce:  MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. More | Follow @MichaelGFierce

@EmilyWFierce: Global infectious diseases are infiltrating the Times' crossword puzzles. Here's a roundup of clues: More | Follow @EmilyWFierce

> Virtual Finger provides faster, better way to study 3D images. Item

> Virtual reality headset and Google Glass team up in Spanish surgery. Report

Pharma News

@FiercePharma: Top-read on FP this weekend: Sun issues third recall since announcing deal to buy Ranbaxy. Article | Follow @FiercePharma

@TracyStaton: ICYMI: MannKind says it won't launch #Afrezza without a partner. We updated our story. | Follow @TracyStaton

@EricPFierce: ICYMI last week: Weak link in the supply chain. Pharmacist walks out of NY hospital with 1,500 oxycodone tabs. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Solid PhIII brings Sanofi closer to blockbuster dengue sales. FierceVaccines story | Follow @CarlyHFierce

> Shire finally comes to AbbVie's buyout table, thanks to $53B-plus bid. Story

> Riled by $84,000 Sovaldi, Senate panel digs into Gilead's Pharmasset buy. More

> China indicts PI and his American wife for 'illegal' activities in GSK bribery probe. Report

> Teva's picked its next chairman, rebel investor Landa says--and he's not in favor. News

CRO News

> China's HD Bio teams with Marshall U. for cancer R&D. Article

> CMOs eye Russia for growth. Item

> InVentiv joins a nonprofit effort to make trials more efficient. News

> Risk-sharing CRO Ergomed banks $18.9M and awaits a U.K. IPO. Story

> U.K. CRO emerges from $100M in deals with plans for more M&A. Article

Biotech IT News

> Google creates new cash source for European biotech IT startups with $100M VC fund. News

> Row over IT focus of Europe's brain project prompts 280 scientists to threaten a boycott. Story

> PHT prioritizes Android over Apple in preparation for 'bring your own device' trials. Article

> FDA warns Gilead over 'misleading' paid search link. Item

> After working to mimic the brain for 9 years, Numenta reflects on limitations of today's hardware. Story

Animal Health News

> PEDv diagnostic hits market as vets predict 2.5 million more deaths. Story

> U.K. animal care company profits from generic pet meds. Article

> Industry Voices: How to win at animal health. Report

> Vets may soon be able to carry scheduled drugs. News

> Report: China animal vaccine market up by 26%. Story